Nephrolithiasis-induced ESRD: Frequency, causes and prevention;Insuffisance rénale terminale d'origine lithiasique: Fréquence, causes et prévention

Nephrologie et Therapeutique

Volumn 1, Issue 5, 2005, Pages 301-310

  Jungers, Paul ^a   Joly, Dominique ^a   Barbey, Frédéric ^b   Choukroun, Gabriel ^c   Daudon, Michel ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

End stage renal disease; Epidemiology; Hereditary stone diseases; Nephrocalcinosis; Nephrolithiasis

Indexed keywords

2,8 DIHYDROXYADENINE; CALCIUM; CYSTEINE; URIC ACID;

2,8 DIHYDROXYADENINURIA; ARTICLE; CALCIUM STONE; DIAGNOSTIC ERROR; DIALYSIS; GENETIC DISORDER; HUMAN; HYPEROXALURIA; INCIDENCE; KIDNEY FAILURE; KIDNEY INFECTION; NEPHROLITHIASIS; PREVALENCE; URIC ACID STONE;

EID: 28344452207     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2005.08.001     Document Type: Article

References (46)

1. Gambaro G, Favaro S, D'Angelo A. Risk for renal failure in nephrolithiasis. Am J Kidney Dis 2001;37:233-43.
2. Worcester E, Parks JH, Josephson MA, Thisted RA, Coe FL. Causes and consequences of kidney loss in patients with nephrolithiasis. Kidney Int 2003;64:2204-13.
3. Streem SB. Long-term incidence and risk factors for recurrent stones following percutaneous nephrostolithotomy or percutaneous nephrostolithotomy- extracorporeal shock wave lithotripsy for infection related calculi. J Urol 1995;153:584-7.
4. Teichman JM, Long RD, Hulbert JC. Long-term renal fate and prognosis after staghorn calculus management. J Urol 1995;153:1403-7.
5. Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 2004;44:799-805.
6. Gambaro G, Vezzoli G, Casari G, Rampoldi L, D'Angelo A, Borghi L. Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis 2004;44:963-86.
7. Marangella M, Bruno M, Cosseddu D, Manganaro M, Tricerri A, Vitale C, et al. Prevalence of chronic renal insufficiency in the course of idiopathic recurrent calcium stone disease: risk factors and patterns of progression. Nephron 1990;54:302-6.
8. Gupta M, Bolton DM, Gupta PN, Stoller ML. Improved renal function following aggressive treatment of urolithiasis and concurrent mild to moderate renal insufficiency. J Urol 1994;152:1086-90.
9. Chandhoke PS, Albala DM, Clayman RV. Long-term comparison of renal function in patients with solitary kidneys and/or moderate renal insufficiency undergoing extracorporeal shock wave lithotripsy or percutaneous nephrolithotomy. J Urol 1992;147:1226-30.
10. Goel MC, Ahlawat R, Kumar M, Kapoor R. Chronic renal failure and nephrolithiasis in a solitary kidney: role of intervention. J Urol 1997;157:1574-7.
11. Singh I, Gupta NP, Hemal AK, Aron M, Dogra PN, Seth A. Efficacy and outcome of surgical intervention in patients with nephrolithiasis and chronic renal failure. Int Urol Nephrol 2001;33:293-8.
12. Degoulet P, Reach I, Rozenbaum W, Aime F, Devries C, Berger C, et al. Société de néphrologie, programme dialyse informatique. VI. Survie et facteurs de risque. J Urol Nephrol (Paris) 1979;85:909-62.
13. Jungers P, Choukroun G, Robino C, Massy ZA, Taupin P, Labrunie M, et al. Epidemiology of end-stage renal disease in the Île-de-France area: a prospective study in 1998. Nephrol Dial Transplant 2000;15:2000-6.
14. System USRD. II. Incidence and prevalence of ESRD. Am J Kidney Dis 1999;34:S40-50.
15. Daudon M, Jungers P. Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi. Nephron Physiol 2004;98:31-6.
16. Daudon M, Jungers P, Lacour B. Intérêt clinique de l'étude de la cristallurie. Ann Biol Clin (Paris) 2004;62:379-93.
17. Ceballos-Picot I, Perignon JL, Hamet M, Daudon M, Kamoun P. 2,8-Dihydroxyadenine urolithiasis, an underdiagnosed disease. Lancet 1992;339:1050-1.
18. Marangella M. Transplantation strategies in type 1 primary hyperoxaluria: the issue of pyridoxine responsiveness. Nephrol Dial Transplant 1999;14:301-3.
19. Marangella M, Petrarulo M, Cosseddu D. End-stage renal failure in primary hyperoxaluria type 2. N Engl J Med 1994;330:1690.
20. Glicklich D, Gruber HE, Matas AJ, Tellis VA, Karwa G, Finley K, et al. 2,8-dihydroxyadenine urolithiasis: report of a case first diagnosed after renal transplant. Q J Med 1988;68:785-93.
21. Simmonds H, Van Acker KJ, Sahota AS. 2,8-Dihydroxy-adenine urolithiasis. Lancet 1992;339:1295-6.
22. Fye KH, Sahota A, Hancock DC, Gelb AB, Chen J, Sparks JW, et al. Adenine phosphoribosyltransferase deficiency with renal deposition of 2,8-dihydroxyadenine leading to nephrolithiasis and chronic renal failure. Arch Intern Med 1993;153:767-70.
23. Gagne ER, Deland E, Daudon M, Noel LH, Nawar T. Chronic renal failure secondary to 2,8-dihydroxyadenine deposition: the first report of recurrence in a kidney transplant. Am J Kidney Dis 1994;24:104-7.
24. de Jong DJ, Assmann KJ, De Abreu RA, Monnens LA, Van Liebergen FJ, Dijkman HB, et al. 2,8-Dihydroxyadenine stone formation in a renal transplant recipient due to adenine phosphoribosyltransferase deficiency. J Urol 1996;156:1754-5.
25. Brown HA. Recurrence of 2,8-dihydroxyadenine tubulointerstitial lesions in a kidney transplant recipient with a primary presentation of chronic renal failure. Nephrol Dial Transplant 1998;13:998-1000.
26. Eller P, Rosenkranz AR, Mark W, Theurl I, Laufer J, Lhotta K. Four consecutive renal transplantations in a patient with adenine phosphoribosyltransferase deficiency. Clin Nephrol 2004;61:217-21.
27. Wharton R, D'Agati V, Magun AM, Whitlock R, Kunis CL, Appel GB. Acute deterioration of renal function associated with enteric hyperoxaluria. Clin Nephrol 1990;34:116-21.
28. Edvardsson V, Palsson R, Olafsson I, Hjaltadottir G, Laxdal T. Clinical features and genotype of adenine phosphoribosyltransferase deficiency in Iceland. Am J Kidney Dis 2001;38:473-80.
29. Hoffmann M, Talaska A, Bocquet JP, Le Monies de Sagazan H, Daudon M. Insuffisance rénale aiguë et 2,8-dihydroxyadéninurie. Nephrologie 2004;25:297-300.
30. Jungers P, Daudon M, Conort P. Lithiase rénale: diagnostic et traitement. Paris: Flammarion Médecine Sciences; 1999.
31. Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol 2002;168:1307-14.
32. Scheinman SJ. X-linked hypercalciuric nephrolithiasis: clinical syndromes and chloride channel mutations. Kidney Int 1998;53:3-17.
33. Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, et al. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 2001;12:1872-81.
34. Sliman GA, Winters WD, Shaw DW, Avner ED. Hypercalciuria and nephrocalcinosis in the oculocerebrorenal syndrome. J Urol 1995;153:1244-6.
35. Tricot L, Yahiaoui Y, Teixeira L, Benabdallah L, Rothschild E, Juquel JP, et al. End-stage renal failure in Lowe syndrome. Nephrol Dial Transplant 2003;18:1923-5.
36. Cochat P, Jouvenet M, Pellet H, Feber J, Martin X, Divry P. Les maladies héréditaires responsables de lithiase rénale. Rev Prat 1997;47:1554-8.
37. Daudon M, Bader CA, Jungers P. Urinary calculi: review of classification methods and correlations with etiology. Scanning Microsc 1993;7:1081-104 (discussion 104-6).
38. Daudon M, Estepa L, Lacour B, Jungers P. Unusual morphology of calcium oxalate calculi in primary hyperoxaluria. J Nephrol 1998;11(Suppl 1):51-5.
39. Daudon M, Hennequin C, Boujelben G, Lacour B, Jungers P. Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int 2005;67:1934-43.
40. Estepa-Maurice L, Hennequin C, Marfisi C, Bader C, Lacour B, Daudon M. Fourier transform infrared microscopy identification of crystal deposits in tissues: clinical importance in various pathologies. Am J Clin Pathol 1996;105:576-82.
41. Cochat P. Primary hyperoxaluria type 1. Kidney Int 1999;55:2533-47.
42. Chow GK, Streem SB. Medical treatment of cystinuria: results of contemporary clinical practice. J Urol 1996;156:1576-8.
43. Joly D, Rieu P, Mejean A, Gagnadoux MF, Daudon M, Jungers P. Treatment of cystinuria. Pediatr Nephrol 1999;13:945-50.
44. Barbey F, Joly D, Rieu P, Mejean A, Daudon M, Jungers P. Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol 2000;163:1419-23.
45. Daudon M, Cohen-Solal F, Barbey F, Gagnadoux MF, Knebelmann B, Jungers P. Cystine crystal volume determination: a useful tool in the management of cystinuric patients. Urol Res 2003;31:207-11.
46. Hoppe B, Leumann E. Diagnostic and therapeutic strategies in hyperoxaluria: a plea for early intervention. Nephrol Dial Transplant 2004;19:754-6.